晚期非小细胞肺癌的药物治疗进展.pdf

中国药物应用与监测 2014年12月 第11 卷 第6期 Chinese Journal of Drug Application and Monitoring, Vol.11, No.6, December 2014 ·专家论坛· 晚期非小细胞肺癌的药物治疗进展 胡　毅 1，陶海涛 1,2（1.解放军总医院肿瘤内一科，北京 100853；2.南开大学医学院，天津 300100） [ 摘要]　肺癌目前仍是死亡率较高的恶性肿瘤。近年来随着分子靶向治疗的进展，非小细胞肺癌的治疗已经取得了长足的 进步。许多转化性临床研究结果带来近期疗效、生活质量尤其是生存的显著提高。传统的化疗是非小细胞肺癌治疗的基石， 是野生型以及突变未知患者治疗的首选；分子靶向治疗则为敏感突变的患者带来了革命性的转变，是目前治疗的中流砥柱； 而免疫治疗在免疫检查点抑制剂上的突破也结束了长期混沌的状态，成为非小细胞肺癌治疗的新兴力量。而无论是化疗、靶 向治疗还是免疫治疗，基于肿瘤分子病理改变的精确治疗是目前非小细胞肺癌治疗发展的趋势。 [关键词]　非小细胞肺癌；化疗；分子靶向治疗；免疫治疗 [中图分类号]　R979.1　　 [文献标识码]　A　 [文章编号]　1672 – 8157(2014)06 – 0329 – 05 New progress of drug therapy in advanced non-small cell lung cancer HU Yi1, TAO Hai-tao1,2(1. Medical Oncology Department Ⅰof PLA General Hospital, Beijing 100853, China; 2. School of Medicine, Nankai University, Tianjin 300100, China) [ABSTRACT]　Lung cancer is the leading cause of cancer mortality. Due to the progress in molecular target therapy, great progress has been achieved in advanced non-small cell lung cancer (NSCLC). Many treatments have been demonstrated to improve the objective remission rate, quality of life and even the progressive free survival and overall survival in translational researches. Traditional chemotherapy is very important for NSCLC patients, especially for those wild-type or unknown gene mutation patients; the progress in molecular target therapy just revolutionize the treatment of NSCLC and become the ? rst choice for those patients with gene sensitive mutation; the progresses of drugs which target speci? c checkpoint of immune system have led the immunotherapy to new heights, immunotherapy become the new choice for NSCLC. No matter chemotherapy, target therapy or immunotherapy, the treatments based on exact change of the molecular pathogenesis are the development direction of NSCLC. [KEY WORDS]　Non-small cell lung cancer; Chemotherapy; Molecular target therapy; Immunothera